



Financial Tear Sheet

Corporate Profile

Cambrex Corporation is a custom development and manufacturing organization that specializes in products and services that accelerate the development and commercialization of small molecule therapeutics.

We offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.

Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage forms.

Primary IR Contact

Stephanie LaFiura
Investor Relations Associate
Phone: 201-804-3037
Fax: 201-804-9852
E-mail:
stephanie.lafiura@cambrex.com

Stock Performance

Symbol CBM (Common Stock)

Exchange NYSE (US Dollar)

Price \$48.00

Change (%) ▼ 0.3 (0.62%)

Volume 350,330

Data as of November 17, 2017 3:24 p.m. ET

Management

Steven M. Klosk President and Chief Executive Officer

Shawn P. Cavanagh Executive Vice President and Chief Operating Officer

Samantha M. Hanley Vice President, General Counsel and Secretary

Gregory P. Sargen Executive Vice President, Corporate Development and Strategy

Tom Vadaketh Executive Vice President and Chief Financial Officer

Recent Headlines & Events

There are currently no events scheduled.

Date	Title
November 09, 2017	CAMBREX WINS API DEVELOPMENT AWARD AT CPhI WORLDWIDE FOR SECOND CONSECUTIVE YEAR
November 08, 2017	Cambrex Invests in New Small Scale Capacity at Its Charles City, Iowa Facility
November 07, 2017	Cambrex Reports Third Quarter 2017 Financial Results

SEC Filings

Filing Date	Form
November 07, 2017	10-Q
November 07, 2017	8-K
November 03, 2017	8-K
November 03, 2017	8-K

Data provided by Nasdaq. Minimum 15 minutes delayed.